Monitoring of minimal residual disease in chronic myeloid leukemia

Hematology/Oncology Clinics of North America

Volumn 18, Issue 3, 2004, Pages 657-670

  Faderl, Stefan ^a   Hochhaus, Andreas ^b   Hughes, Timothy ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HOUSEKEEPING GENE; HUMAN; MINIMAL RESIDUAL DISEASE; NUCLEIC ACID AMPLIFICATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

DRUG MONITORING; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL;

EID: 3242794241     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.03.010     Document Type: Review

References (56)

1. Faderl S., Talpaz M., Estrov Z., et al. The biology of chronic myeloid leukemia. N Engl J Med. 341:1999;164-172
2. Seong D.C., Song M.Y., Henske E.P., et al. Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. Blood. 83:1994;2268-2273
3. Seong D.C., Kantarjian H.M., Ro J.Y., et al. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 86:1995;2343-2349
4. Buno I., Wyatt W.A., Zinsmeister A.R., et al. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood. 92:1998;2315-2321
5. Dewald G.W., Wyatt W.A., Juneau A.L., et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 91:1998;3357-3365
6. Schoch C., Schnittger S., Bursch S., et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 16:2002;53-59
7. Kaeda J., Chase A., Goldman J.M. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukemia. Acta Haematol. 107:2002;64-67
8. Hughes T.P., Morgan G.J., Martiat P., et al. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood. 77:1991;874-878
9. Miyamura K., Tahara T., Tanimoto M., et al. Long persistent bcr-abl-positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients. Blood. 81:1993;1089-1093
10. Gaiger A., Lion T., Kalhs P., et al. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia. 7:1993;1766-1772
11. Faderl S., Talpaz M., Kantarjian H.M., et al. Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making? Blood. 93:1999;2755-2759
12. Hochhaus A. Minimal residual disease in chronic myeloid leukaemia patients. Best Pract Res Clin Haematol. 15:2002;159-178
13. van Dongen J.J.M., MacIntyre E.A., Gabert J.A., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia. 12:1999;1901-1928
14. Bagg A. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. J Mol Diag. 4:2002;1-10
15. Lion T., Henn T., Gaiger A., et al. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet. 341:1993;275-276
16. Cross N.C.P., Lin F., Chase A., et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukaemia after bone marrow transplantation. Blood. 82:1993;1929-1936
17. Heid C.A., Stevens J., Livak K.J., et al. Real time quantitative PCR. Genome Res. 6:1996;986-994
18. Mensink E., van de Locht A., Schattenberg A., et al. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative PCR. Br J Haematol. 102:1998;768-774
19. Branford S., Hughes T.P., Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 107:1999;587-599
20. Oehler V.G., Radich J.P. Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. Curr Oncol Rep. 5:2003;426-435
21. Radich J.P., Gehly G., Gooley T., et al. Polymerase chain reaction detection of BCR/ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 85:1995;2632-2638
22. Potter M.N., Cross N.C.P., van Dongen J.J., et al. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. Leukemia. 7:1993;1302-1314
23. Reiter E., Greinix H.T., Keil F., et al. Long-term follow up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol. 78:1999;507-513
24. Pichert G., Roy D.-C., Gonin R., et al. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 13:1995;1704-1713
25. Gratwohl A., Brand R., Apperley J., et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood. 100:2002;3877-3886
26. Mackinnon S., Barnett L., Heller G. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 17:1996;643-647
27. Radich J.P., Gooley T., Bryant E., et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood. 98:2001;1701-1707
28. Olavarria E., Kanfer E., Szydlo R., et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 97:2001;1560-1565
29. Lin F., van Rhee F., Goldman J.M., et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 87:1996;4473-4478
30. Kantarjian H.M., Giles F.J., O'Brien S., et al. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin N Am. 12:1998;31-80
31. Hochhaus A., Reiter A., Saussele S., et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood. 95:2000;62-66
32. Hochhaus A., Lin F., Reiter A., et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood. 87:1996;1549-1555
33. Kurzrock R., Estrov Z., Kantarjian H., et al. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clin Oncol. 16:1998;1526-1531
34. Talpaz M., Estrov Z., Kantarjian H., et al. Persistence of dormant leukemic progenitors during interferon-based remission in chronic myelogenous leukemia: an analysis by polymerase chain reaction of individual colonies. J Clin Invest. 94:1994;1383-1389
35. Pasternak G., Pasternak L. Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood. Ann Hematol. 68:1994;9-14
36. Chomel J.C., Brizard F., Veinstein A., et al. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation. Blood. 95:2000;404-408
37. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004
38. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 349:2003;1423-1432
39. Branford S., Rudzki Z., Harper A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 17:2003;2401-2409
40. Müller M.C., Gattermann N., Lahaye T., et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C. Leukemia. 17:2003;2392-2400
41. Kantarjian H.M., Talpaz M., Cortes J., et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 9:2003;160-166
42. Cortes J.E., Talpaz M., Giles F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 101:2003;3794-3800
43. Marktel S., Marin D., Foot N., et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 88:2003;260-267
44. Deininger M.W. Cytogenetic studies in patients on imatinib. Semin Hematol. 40(2 Suppl 3):2003;50-55
45. Andersen M.K., Pedersen-Bjergaard J., Kjeldsen L., et al. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia. 16:2002;1390-1393
46. Lion T. Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects. Leukemia. 10:1996;896-900
47. Hughes T., Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol. 40(Suppl 2):2003;62-68
48. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356
49. Cross N.C., Melo J.V., Feng L., et al. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia. 8:1994;186-189
50. Tobal K., Saunders M.J., Grey M.R., et al. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcription polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia. Br J Haematol. 90:1995;608-615
51. Miyamoto T., Nagafuji K., Akashi K., et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood. 87:1996;4789-4796
52. Biernaux C., Loos M., Sels A., et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 86:1995;3118-3122
53. Bose S., Deininger M., Gora-Tybor J., et al. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 92:1998;3362-3367
54. Uhr J.W., Scheuermann R.H., Street N., et al. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med. 3:1997;505-509
55. Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia: the European Investigators on Chronic Myeloid Leukemia Group. Bone Marrow Transplant. 14:1994;505-509
56. Martinelli G., Montefusco V., Testoni N., et al. Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. Haematologica. 85:2000;653-658